AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25183688 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic L. plantarum IS-10506 (10(10)CFU/day)
Number of subjects: 48
Study 25183688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of probiotic L. plantarum IS-10506 (10(10)CFU/day) and zinc (8mg elemental zinc)
Number of subjects: 48
Study 25183688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22464088 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing training program (DBTP)
Number of subjects: 30
Study 20482515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone, 50 mg
Number of subjects: 4000
Study 20482515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular naltrexone (active for one month)
Number of subjects: 4000
Study 20482515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 4000
Study 20482515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone, higher doses
Number of subjects: 4000
Study 18025916 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone problem-solving counseling by baccalaureate nurses
Number of subjects: 175
Study 18025916 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study 15228129 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin 1% topical gel (BP/C)
Number of subjects: 50
Study 15228129 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study 12568205 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg for 8 weeks
Number of subjects: 30
Study 12568205 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg daily after washout
Number of subjects: 30
Study 9525448 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (200 microg fluticasone propionate twice daily; n = 16)
Number of subjects: 33
Study 9525448 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo nasal spray (n = 17)
Number of subjects: 33
Study 8580622 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA antibodies to BSA
Number of subjects: 104
Study 8580622 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies to BSA
Number of subjects: 104
Study 8580622 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA antibodies to ovalbumin
Number of subjects: 104
Study 8580622 — intervention group
Group type: COMPARATOR
Intervention: IgG antibodies to ovalbumin
Number of subjects: 104
Study 8580622 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA antibodies to beta-lactoglobulin
Number of subjects: 104
Study 8580622 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA antibodies to cow's milk
Number of subjects: 104
Study 2569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60
Study 2569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 60
Study 2569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural butorphanol
Number of subjects: 60
Study 2569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine
Number of subjects: 60
Study 138578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 mug to 80 mug
Number of subjects: 20
Study 138578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 mug
Number of subjects: 20
Study 138578 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 20
Study 138578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31248548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus Aspirin
Number of subjects: 1000
Study 31248548 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1000
Study 30168004 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet 1-20 mg (single dose)
Number of subjects: 66
Study 30168004 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet 6 and 12 mg (multiple doses)
Number of subjects: 66
Study 30168004 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet up to 12 mg (multiple doses)
Number of subjects: 66
Study 30168004 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet up to 20 mg (single dose)
Number of subjects: 66
Study 30168004 — intervention group
Group type: COMPARATOR
Intervention: Evocalcet (compared to cinacalcet)
Number of subjects: 66
Study 26657820 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard + Therapeutic Education System (TES)
Number of subjects: 160
Study 26657820 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 160
Study 24560135 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 267 mg daily
Number of subjects: 13
Study 24560135 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg daily
Number of subjects: 13
Study 23177751 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment
Number of subjects: 42
Study 23177751 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 42
Study 23177751 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual judgments of voice qualities
Number of subjects: 42
Study 23177751 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic measures
Number of subjects: 42
Study 20636275 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV/ritonavir (SQV/r) 1000 mg/ritonavir 100 mg BID
Number of subjects: 28
Study 20636275 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual treatment)
Number of subjects: 28
Study 17443204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 29
Study 17443204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16321761 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573
Study 16321761 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and temozolomide
Number of subjects: 573
Study 12696650 — intervention group
Group type: EXPERIMENTAL
Intervention: Automobile mechanics (exposed to automotive pollution)
Number of subjects: 29
Study 10638488 — intervention group
Group type: EXPERIMENTAL
Intervention: Caracemide (11 patients)
Number of subjects: 24
Study 10638488 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoharringtonine (13 patients)
Number of subjects: 24
Study 7595738 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (IFN‐alpha 2a) 20 x 10(6) U/m2 administered three times each week for 12 weeks
Number of subjects: 262
Study 7595738 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 262
Study 7595738 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (IFN‐alpha 2a)
Number of subjects: 262
Study 2147842 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (total dose of 1.5 mg/kg)
Number of subjects: 10
Study 2147842 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprussiate (3 micrograms/kg/mn)
Number of subjects: 10
Study 2147842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 10
Study 2147842 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (Enoximone, Dobutamine, Sodium nitroprussiate)
Number of subjects: 10
Study 7247053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (21 calories/gm nitrogen)
Number of subjects: 40
Study 7247053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet (138 calories/gm nitrogen)
Number of subjects: 40
Study 31027300 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber cereal (90 g, 11 g fiber/90 g) consumed at Sohor for 20 consecutive days
Number of subjects: 81
Study 31027300 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet intake (control group)
Number of subjects: 81
Study 31027300 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber cereal (90 g, 11 g fiber/90 g)
Number of subjects: 81
Study 27809609 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational Device
Number of subjects: 21
Study 27809609 — intervention group
Group type: COMPARATOR
Intervention: Control Device: FDA‐cleared syringe driver with FDA‐cleared infusion set
Number of subjects: 21
Study 27809609 — intervention group
Group type: COMPARATOR
Intervention: Control Device: FDA‐cleared syringe driver attached to investigational device
Number of subjects: 21
Study 27809609 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices (Investigational and Control)
Number of subjects: 21
Study 25432497 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 0
Study 25016139 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-unit posterior metal-ceramic FDP (Au-Pd-Ag alloy and InLine POM)
Number of subjects: 89
Study 25016139 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-ceramic FDP (ZirCAD and ZirPress)
Number of subjects: 89
Study 25016139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of FDPs
Number of subjects: 89
Study 22430709 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Development Teams (CDT) approach
Number of subjects: 0
Study 22430709 — intervention group
Group type: COMPARATOR
Intervention: Standard individualized implementation methods
Number of subjects: 0
Study 21062616 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 196
Study 21062616 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride to high-density lipoprotein (TG:HDL) ratio
Number of subjects: 196
Study 21062616 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 196
Study 17619868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (10 mg)
Number of subjects: 38
Study 17619868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine (10 mg)
Number of subjects: 38
Study 15776301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver (PR)
Number of subjects: 75
Study 15776301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 75
Study 15776301 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐GST concentrations (> 490 microg L(‐1))
Number of subjects: 75
Study 15776301 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NPR)
Number of subjects: 75
Study 12081988 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 2763
Study 12081988 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 2763
Study 12081988 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT) with adjustment for postrandomization statin use
Number of subjects: 2763
Study 9875580 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV-ddC
Number of subjects: 2467
Study 9875580 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV
Number of subjects: 2467
Study 9875580 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV-ddl
Number of subjects: 2467
Study 9875580 — intervention group
Group type: EXPERIMENTAL
Intervention: ddl
Number of subjects: 2467
Study 9875580 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2467
Study 9875580 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 2467
Study 7840322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplements
Number of subjects: 0
Study 7840322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7840322 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger reference subjects (< 33 years old) taking no supplement
Number of subjects: 0
Study 7840322 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 2367600 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (n = 6)
Number of subjects: 17
Study 2367600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 17
Study 6250106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Number of subjects: 0
Study 6250106 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 6250106 — intervention group
Group type: COMPARATOR
Intervention: Thiethylperazine
Number of subjects: 0
Study 31652232 — intervention group
Group type: EXPERIMENTAL
Intervention: SELF‐FIT intervention
Number of subjects: 667
Study 31652232 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practices)
Number of subjects: 667
Study 31735251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotations condition (n = 20)
Number of subjects: 57
Study 31735251 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposite directions condition (n = 20)
Number of subjects: 57
Study 31735251 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 17)
Number of subjects: 57
Study 27631386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Serial Casting (SC)
Number of subjects: 51
Study 27631386 — intervention group
Group type: COMPARATOR
Intervention: Control group (PT only)
Number of subjects: 51
Study 25978742 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 46
Study 25978742 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 46
Study 25978742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24229549 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 128
Study 24229549 — intervention group
Group type: COMPARATOR
Intervention: Enhanced community standard
Number of subjects: 128
Study 24229549 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 128
Study 20825814 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV rapid testing in the emergency department (ED)
Number of subjects: 121
Study 20825814 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted HIV screening
Number of subjects: 121
Study 20825814 — intervention group
Group type: COMPARATOR
Intervention: Testing at nonpeak hours
Number of subjects: 121
Study 20825814 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic testing
Number of subjects: 121
Study 20825814 — intervention group
Group type: COMPARATOR
Intervention: No testing or 'other'
Number of subjects: 121
Study 19297309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome (CFS) patients
Number of subjects: 205
Study 19297309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome (CFS) patients and PBC group
Number of subjects: 205
Study 17892996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of mononuclear bone marrow cells (mBMCs)
Number of subjects: 100
Study 17892996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 16841333 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol (400 IU/day) and beta‐carotene (30 mg/day) supplements
Number of subjects: 540
Study 16841333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 540
Study 12968238 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of low‐dose fenoldopam (0.1‐0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B)
Number of subjects: 160
Study 12968238 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (group A)
Number of subjects: 160
Study 11013196 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 200
Study 9042557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 20
Study 1623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Niguldipine (0.3, 0.6, and 0.9 mg intravenously; 8 and 16 mg orally)
Number of subjects: 0
Study 1623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (2 mg intravenously; 20 mg orally)
Number of subjects: 0
Study 1623694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6378555 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic wound ring drape (Opdrape, Triplus)
Number of subjects: 140
Study 6378555 — intervention group
Group type: COMPARATOR
Intervention: No plastic wound ring drape (control group)
Number of subjects: 140
Study 6378555 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received preoperative systemic antibiotic prophylaxis
Number of subjects: 140
Study 6378555 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic wound ring drape
Number of subjects: 140
Study 30990057 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention group (IG) received a 90-minute session including psychoeducation, relaxation training, and coping skills.
Number of subjects: 26
Study 30990057 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) did not receive any psychological intervention.
Number of subjects: 26
Study 31093303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture during paired-associative stimulation (PAS)
Number of subjects: 0
Study 31093303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 31093303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation techniques
Number of subjects: 0
Study 29303212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel
Number of subjects: 50
Study 29303212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methylprednisolone cream
Number of subjects: 50
Study 29303212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 25884010 — intervention group
Group type: EXPERIMENTAL
Intervention: NP001 2 mg/kg
Number of subjects: 136
Study 25884010 — intervention group
Group type: EXPERIMENTAL
Intervention: NP001 1 mg/kg
Number of subjects: 136
Study 25884010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 23791499 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Extracorporeal Circulation (MECC)
Number of subjects: 120
Study 23791499 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cardiopulmonary Bypass (CPB)
Number of subjects: 120
Study 21515889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Number of subjects: 37
Study 21515889 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 18837187 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for thrombophilia
Number of subjects: 0
Study 18837187 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16772623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 93
Study 16772623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 15080830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual swallow immunotherapy (SLIT)
Number of subjects: 161
Study 15080830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 11399215 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy
Number of subjects: 155
Study 11399215 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive-behavioral therapy
Number of subjects: 155
Study 9429007 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic medicine
Number of subjects: 68
Study 9429007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8484371 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult blood testing for colorectal cancer screening
Number of subjects: 0
Study 8484371 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3435119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpimizole (100 mg to 2000 mg)
Number of subjects: 0
Study 3435119 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime and cephalothin (positive controls)
Number of subjects: 0
Study 3435119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpimizole (500 mg and 1000 mg twice-daily)
Number of subjects: 0
Study 29383525 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced (CE) cadaver-specific post-mortem computed tomography (PMCT)
Number of subjects: 132
Study 29383525 — intervention group
Group type: COMPARATOR
Intervention: Non-enhanced (NE) cadaver-specific PMCT
Number of subjects: 132
Study 27075708 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy‐diabetes (BFST‐D) via telehealth
Number of subjects: 90
Study 27075708 — intervention group
Group type: COMPARATOR
Intervention: Traditional (Clinic) treatment
Number of subjects: 90
Study 25127725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (targeting systolic blood pressure < 120 mmHg)
Number of subjects: 3099
Study 25127725 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (targeting systolic blood pressure < 140 mmHg)
Number of subjects: 3099
Study 24369254 — intervention group
Group type: EXPERIMENTAL
Intervention: INFα‐2b monotherapy (5×10(6), three times a week)
Number of subjects: 161
Study 24369254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with entecavir (0.5 mg/day) plus adefovir (10 mg/day)
Number of subjects: 161
Study 20704726 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month dietary and physical activity intervention including guidelines for vegetable and fruit intake, fat intake, fiber intake, alcohol consumption, and physical activity (30 minutes of brisk walking, 5 or more days per week).
Number of subjects: 94
Study 20704726 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month dietary and physical activity intervention.
Number of subjects: 94
Study 20704726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 94
Study 18391288 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D first person shooter (FPS) game training
Number of subjects: 22
Study 18391288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-D non-FPS game training
Number of subjects: 22
Study 18391288 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 18391288 — intervention group
Group type: EXPERIMENTAL
Intervention: Past experience with FPS games
Number of subjects: 22